Nat. Med. 23, 540–547 (2017); published online 5 May 2017; corrected after print 5 May 2017
In the version of this article published in print, Jeffrey A Bluestone was missing an affiliation. His affiliation information has been changed to include the Parker Institute for Cancer Immunotherapy in San Francisco, California. Accordingly, the affiliation information for Carl H June has been updated to distinguish the Parker Institute from the University of Pennsylvania; these are now two separate affiliations. All affiliation numbers have been revised. The error did not appear in the HTML and PDF versions of the article.
Additional information
The online version of the original article can be found at 10.1038/nm.4321
Rights and permissions
About this article
Cite this article
June, C., Warshauer, J. & Bluestone, J. Correction: Corrigendum: Is autoimmunity the Achilles' heel of cancer immunotherapy?. Nat Med 23, 1004 (2017). https://doi.org/10.1038/nm0817-1004b
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm0817-1004b
This article is cited by
-
Germline variants associated with toxicity to immune checkpoint blockade
Nature Medicine (2022)
-
When worlds collide: Th17 and Treg cells in cancer and autoimmunity
Cellular & Molecular Immunology (2018)
